
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today: an ADC that targets the tumor’s surroundings, a new way to block complement in myasthenia gravis, and bispecifics designed to hit only cells that carry two targets at once.
First,
Next,
And finally,
That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.
Key takeaways
- New ADC targets: MICVO’s early data support targeting the tumor matrix, but phase 3 data will be needed to confirm it.
- Competing modalities: Myasthenia gravis now has two newly approved C5 inhibitors, an antibody given weekly and an siRNA given four times a year.
- Precision targeting: AbbVie’s deal shows investment in bispecifics engineered to tell tumor cells from healthy ones.
Related to this article









